https://www.selleckchem.com/products/cb-839.html
Glycemic control is suboptimal in many individuals with type 2 diabetes. Although use of flash continuous glucose monitoring (CGM) has demonstrated A1C reductions in patients with type 2 diabetes treated with a multiple daily injection or insulin pump therapy regimen, the glycemic benefit of this technology in patients with type 2 diabetes using nonintensive treatment regimens has not been well studied. This retrospective, observational study used the IBM Explorys database to assess changes in A1C after flash CGM prescription in a large
Like
Comment
Share
